Dermatologic Clinic, Department of Medical Sciences, University of Turin Medical School, Torino, Italy.
Laboratory of Immunogenetics, Department of Medical Sciences, University of Torino, 10126 Torino, Italy.
Dis Markers. 2022 Feb 24;2022:3424413. doi: 10.1155/2022/3424413. eCollection 2022.
Reports on the expression of CD38 in Sézary syndrome (SS), erythrodermic primary cutaneous T cell lymphoma with leukemic involvement, are limited. The aim of the present study is the analysis of the expression of CD38 by skin-infiltrating mononuclear cells and circulating T lymphocytes in a cohort of SS patients.
SS patients diagnosed since 1985 in our clinic were retrospectively analyzed for CD38 expression in biopsy and blood samples by immunohistochemistry and flow cytometry, respectively.
SS patients show a predominant CD38-negative phenotype on both skin and blood. A subgroup of patients was found expressing CD38 (12 cases) in either the skin (>25% cell infiltrate) or blood (CD4+CD38+ >50%), among whom 4 in the blood, 7 in the skin, and 1 in both blood and skin.
The implications of these observations may be twofold: the relevance in basic science is related to a potential role in immune defense regulation, whilst in perspective CD38 may become a target for antibody therapy, considering the availability of different anti-CD38 monoclonal antibodies.
关于 CD38 在蕈样肉芽肿(SS)中的表达的报告有限,SS 是一种累及白血病的红皮病性原发性皮肤 T 细胞淋巴瘤。本研究旨在分析一组 SS 患者皮肤浸润性单核细胞和循环 T 淋巴细胞中 CD38 的表达。
回顾性分析了自 1985 年以来在我科诊断为 SS 的患者的皮肤和血液活检样本中 CD38 的免疫组化和流式细胞术表达。
SS 患者的皮肤和血液均表现为主要的 CD38 阴性表型。发现一个亚组患者的皮肤(>25%细胞浸润)或血液(CD4+CD38+>50%)中表达 CD38(12 例),其中血液中 4 例,皮肤中 7 例,血液和皮肤中各 1 例。
这些观察结果可能有两方面的意义:基础科学方面的相关性与免疫防御调节方面的潜在作用有关,而从 CD38 可能成为抗体治疗的靶点来看,鉴于有不同的抗 CD38 单克隆抗体,其具有一定的前景。